For:
ads
Product Development
Doing the right thing isn’t enough. The public needs to know

Now is not the time for the industry to be doing good behind closed doors.

The biopharma industry has broken its norms in an all-hands-on-deck ...

Immunomedics doubles in value on Phase III update for TNBC therapy ahead of June PDUFA; names Semerjian CEO

After halting a Phase III trial early due to efficacy in the difficult setting of triple-negative breast cancer, Immunomedics named a new, commercially-experienced CEO to help the ...

COVID-19 roundup: Inovio starts vaccine trial; plus updates from RedHill, Hope, CytoDyn, Gilead, Takeda, AACR and UNC-Emory

Inovio looks to be the second company after Moderna to start a U.S. trial of a COVID-19 vaccine, kicking the study off several months ahead of its previously projected summer trial ...

April 6 Quick Takes: Second anemia approval for BMS, Acceleron therapy; plus EU approves trio of metabolic disease drugs, Dicerna-Alnylam and Axsome

Reblozyl gets second approval
FDA approved Reblozyl luspatercept-aamt from Bristol Myers Squibb Co. (NYSE:BMY) and Acceleron Pharma Inc. (NASDAQ:XLRN) to treat ...

Politics, Policy & Law
Trump administration debate over malaria drugs for COVID-19 illustrates White House conflicts

The debate within the Trump administration over the use of hydroxychloroquine to treat COVID-19, previously reported only through leaks, broke into public view over the weekend and ...

U.K. biopharma COVID-19 fight gets closer to home with PM in ICU, death toll escalating

With Prime Minister Boris Johnson now in the ICU, the urgency for answers to COVID-19 takes on a new dimension in the U.K., and the spotlight on its biopharmas to respond with ...

N.J. biotech group calls for donations of drugs, equipment to fight COVID-19

BioNJ, the New Jersey state biotech trade association, is soliciting donations from its members for the state’s COVID-19 relief effort.

Gov. Phil Murphy’s ...

Deals
Gilead turns to Second Genome for microbiome-based biomarkers to guide stratification, combos

Gilead entered the microbiome space Monday via a partnership with Second Genome to discover biomarkers to guide clinical development of the pharma’s pipeline and identify IBD ...

Finance
Deerfield dives into emerging telemedicine tech with new $840M fund

Deerfield is echoing the message from other investors during the COVID-19 pandemic that early-stage investing will go on with the closing of its new $840 million fund. The firm is ...

BioCentury ISSN 1097-7201